Clinical characteristics and long-term outcomes following pancreatic injury – An international multicenter cohort study

Meijer, Laura L.; Vaalavuo, Yrjö; Regnér, Sara; Sallinen, Ville; Lemma, Aurora; Arnelo, Urban; Valente, Roberto; Westermark, Sofia; An, Dong‐Aolei; Moir, John; Irwin, E; Biesel, Esther A.; Hopt, Ulrich T.; Fichtner‐Feigl, Stefan; Wittel, Uwe A.; Weniger, Maximilian; Karle, Hans; Bloemers, Frank W.; Charnley, Richard; Ruess, Dietrich Alexander; Szatmary, Peter

doi:10.1016/j.heliyon.2023.e17436

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that these studies did not conduct any follow-up after discharge and may have missed the delayed development of T3cDM after trauma [104][105][106]. Although a significant number of patients who developed T3cDM after pancreatic trauma had undergone operative intervention, there are reports of patients with non-operative pancreatic injuries that develop diabetes and endocrine dysfunction [102,107]. Therefore, clinicians need to screen for T3cDM development and progression in all patients who have experienced pancreatic trauma, regardless of whether or not operative resection was performed.…”

Section: Pancreatic Traumamentioning

confidence: 99%

Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma

Wayne,

Benbetka,

Besner

et al. 2024

JCM

View full text Add to dashboard Cite

Type 3c diabetes mellitus (T3cDM), also known as pancreatogenic or pancreoprivic diabetes, is a specific type of DM that often develops as a result of diseases affecting the exocrine pancreas, exhibiting an array of hormonal and metabolic characteristics. Several pancreatic exocrine diseases and surgical procedures may cause T3cDM. Diagnosing T3cDM remains difficult as the disease characteristics frequently overlap with clinical presentations of type 1 DM (T1DM) or type 2 DM (T2DM). Managing T3cDM is likewise challenging due to numerous confounding metabolic dysfunctions, including pancreatic endocrine and exocrine insufficiencies and poor nutritional status. Treatment of pancreatic exocrine insufficiency is of paramount importance when managing patients with T3cDM. This review aims to consolidate the latest information on surgical etiologies of T3cDM, focusing on partial pancreatic resections, total pancreatectomy, pancreatic cancer and trauma.

show abstract

Section: Pancreatic Traumamentioning

confidence: 99%

Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma

Wayne,

Benbetka,

Besner

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Medical conditions are incredibly variable, ranging from acute illnesses like infections and injuries to chronic diseases such as diabetes. Consequently, patient outcomes can range from complete recovery to long-term therapies [4,5]. The access to quality healthcare significantly influences patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Biomaterials for Drug Delivery and Human Applications

Trucillo

2024

Materials

View full text Add to dashboard Cite

Biomaterials embody a groundbreaking paradigm shift in the field of drug delivery and human applications. Their versatility and adaptability have not only enriched therapeutic outcomes but also significantly reduced the burden of adverse effects. This work serves as a comprehensive overview of biomaterials, with a particular emphasis on their pivotal role in drug delivery, classifying them in terms of their biobased, biodegradable, and biocompatible nature, and highlighting their characteristics and advantages. The examination also delves into the extensive array of applications for biomaterials in drug delivery, encompassing diverse medical fields such as cancer therapy, cardiovascular diseases, neurological disorders, and vaccination. This work also explores the actual challenges within this domain, including potential toxicity and the complexity of manufacturing processes. These challenges emphasize the necessity for thorough research and the continuous development of regulatory frameworks. The second aim of this review is to navigate through the compelling terrain of recent advances and prospects in biomaterials, envisioning a healthcare landscape where they empower precise, targeted, and personalized drug delivery. The potential for biomaterials to transform healthcare is staggering, as they promise treatments tailored to individual patient needs, offering hope for improved therapeutic efficacy, fewer side effects, and a brighter future for medical practice.

show abstract